Dashboard
Manage Tickers

CHRS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ubs-downgrades-coherus-biosciences-to-neutral-lowers-price-target-to-15
UBS Downgrades Coherus BioSciences to Neut...
08/16/2024 11:31:33

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:CHRS) from Buy to Neutral and lowers the price target from ...

coherus-biosciences-sees-fy24-rd-and-sga-expenses-250m-265m
Coherus BioSciences Sees FY24 R&D And SG&A...
08/08/2024 21:10:43

coherus-biosciences-q2-2024-adj-eps-014-beats-029-estimate-sales-65000m-beat-61366m-estimate
Coherus BioSciences Q2 2024 Adj. EPS $(0.1...
08/08/2024 20:21:44

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $...

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
08/05/2024 10:51:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...

baird-maintains-outperform-on-coherus-biosciences-lowers-price-target-to-8
Baird Maintains Outperform on Coherus BioS...
07/01/2024 11:20:29

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $9...

coherus-biosciences-to-divest-yusimry-in-40m-upfront-all-cash-transaction
Coherus BioSciences To Divest YUSIMRY In $...
06/27/2024 12:28:23

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
05/24/2024 10:26:23

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...

truist-securities-maintains-buy-on-coherus-biosciences-lowers-price-target-to-7
Truist Securities Maintains Buy on Coherus...
05/13/2024 12:19:13

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

hc-wainwright--co-maintains-buy-on-coherus-biosciences-raises-price-target-to-12
HC Wainwright & Co. Maintains Buy on Coher...
05/10/2024 19:37:15

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price tar...

coherus-biosciences-q1-2024-adj-eps-032-misses-024-estimate-sales-77063m-miss-80248m-estimate
Coherus BioSciences Q1 2024 Adj EPS $(0.32...
05/09/2024 21:15:21

coherus-announces-full-repayment-of-pharmakon-advisors-75m-term-loan
Coherus Announces Full Repayment of Pharma...
05/09/2024 12:46:17

New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of L...

coherus-to-collaborate-with-cancer-research-institute-on-novel-combination-evaluating-loqtorzi-with-enb-therapeutics-enb-003-for-treatment-of-ovarian-cancer
Coherus To Collaborate With Cancer Researc...
05/08/2024 13:01:49

coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-annual-meeting
Coherus Presents Preclinical Data For CHS-...
04/08/2024 12:34:02

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, le...

hc-wainwright--co-maintains-buy-on-coherus-biosciences-lowers-price-target-to-11
HC Wainwright & Co. Maintains Buy on Coher...
03/20/2024 11:19:10

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price tar...

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
03/14/2024 11:33:18

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price...

coherus-biosciences-sees-fy24-rd-and-sga-expenses-250m-265m
Coherus BioSciences Sees FY24 R&D And SG&A...
03/13/2024 20:25:39

recap-coherus-biosciences-q4-earnings
Recap: Coherus BioSciences Q4 Earnings
03/13/2024 20:05:06

coherus-biosciences-q4-2023-adj-eps-062-misses-012-estimate-sales-91524m-miss-96400m-estimate
Coherus BioSciences Q4 2023 Adj EPS $(0.62...
03/13/2024 20:03:43

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of...

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

earnings-preview-for-coherus-biosciences
Earnings Preview For Coherus BioSciences
03/12/2024 16:00:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION